BACKGROUND The primary objective of the FANTOM II Long Lesion study was to evaluate the safety and performance of native coronary artery stenting of lesions 20 mm in length using 1 or more Fantom sirolimus-eluting bioresorbable coronary scaffolds. Fantom is a fully resorbable scaffold, manufactured from...
BACKGROUND Compared with bare-metal stents, drug-eluting stents (DES) reduce major adverse cardiac events (MACE) in the first year after percutaneous coronary intervention (PCI) but still have an ongoing 2% to 3% annual event rate reaching 20% at 5 years and 40% to 50% at 10 years. The DynamX Novolimus-E...
BACKGROUND: While dual antiplatelet therapy (DAPT) constitutes the cornerstone of post-PCI pharmacotherapy, duration of DAPT in high bleeding risk (HBR) patients has not been fully defined especially with regard to sex. The results from the Onyx ONE Clear trial demonstrated favorable safety and efficacy ...
Resumo Introdução e objetivos: Stents Coated with the Biodegradable Polymer on their Abluminal Faces and Elution of Sirolimus Versus Biolimus Elution for the Treatment of de Novo Coronary Lesions (Destiny Trial) é um estudo randomizado de não inferioridade que comparou o stent farmacológico eluído ...
BACKGROUND: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study was designed to examine the safety and effectiveness of 1-month ...
BACKGROUND The Onyx ONE and Onyx ONE CLEAR studies demonstrated favorable safety and effectiveness in patients at high bleeding risk (HBR) who were event-free 1 month following Resolute Onyx zotarolimus-eluting stent (ZES) implantation and were then treated with single antiplatelet therapy (SAPT) through...
BACKGROUND The primary objective of the FANTOM II (Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold) was to evaluate the safety and performance of native coronary artery stenting using the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold by assessing th...
BACKGROUND The long- term clinical outcomes of percutaneous coronary intervention can be improved by replacing metallic drug eluting stents with bioresorbable vascular scaffolds. The MeRes-1 Extend trial was designed to assess the safety and efficacy of a novel thin-strut MeRes100 bioresorbable vascular ...
BACKGROUND The objective of this study is to evaluate safety and performance of the Fantom bioresorbable coronary scaffold in the acute setting of myocardial infarction with unstable lesions and thrombogenic milieu. Fantom (Tyrocore, REVA Medical) is composed mainly of an iodinated, polycarbonate copolym...
Serial evaluation of tissue coverage of a drug-eluting stent with bioresorbable polymer after 1, 2 and 3 months by optical coherence tomography (OCT). Repair Study
